Mantao Chen1, Luyuan Zhang1, Renya Zhan2, Xiujue Zheng3. 1. Division of Neurosurgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, Qingchun Road, Hangzhou, Zhejiang Province, China. 2. Division of Neurosurgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, Qingchun Road, Hangzhou, Zhejiang Province, China. 1196057@zju.edu.cn. 3. Division of Neurosurgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79, Qingchun Road, Hangzhou, Zhejiang Province, China. zxj8065@zju.edu.cn.
Abstract
INTRODUCTION: Glioma is the most common malignant brain tumor in adults. The effects of conventional treatment regimens are still limited to prolonging the survival of patients. Histone deacetylases (HDACs) are potential targets for tumor treatment. Pracinostat is a new type of HDAC inhibitor (HDACi) that has a significant antitumor effect on a variety of tumors. Thus, we aim to investigate the role of pracinostat in human glioma and explored its underlying mechanism. METHODS: Cell viability, proliferation and apoptosis of human glioma cell lines were measured by Cell Counting kit 8 and flow cytometry. Pathway verification and protein interaction were determined by quantitative real-time polymerase chain reaction, Western blotting and immunofluorescence staining. Transwell technology was used to assess the migration and invasion of cells. Clinical significance of TIMP3, MMP9 and MMP2 in glioma was analyzed through The Cancer Genome Atlas (TCGA) database and the Genotype-Tissue Expression (GTEx) database. RESULTS: Functionally, pracinostat not only inhibited proliferation and induced apoptosis but also inhibited migration and invasion in human glioma cell lines. Mechanistically, pracinostat increased the expression of TIMP3 and decreased the expression of MMP2, MMP9 and VEGF in human glioma cells in vitro and in vivo. In addition, pracinostat inhibited both the PI3K/Akt signaling pathway and the STAT3 pathway. CONCLUSIONS: Our results strongly support the potential clinical use of pracinostat as a novel therapy for human glioma in the near future.
INTRODUCTION: Glioma is the most common malignant brain tumor in adults. The effects of conventional treatment regimens are still limited to prolonging the survival of patients. Histone deacetylases (HDACs) are potential targets for tumor treatment. Pracinostat is a new type of HDAC inhibitor (HDACi) that has a significant antitumor effect on a variety of tumors. Thus, we aim to investigate the role of pracinostat in human glioma and explored its underlying mechanism. METHODS: Cell viability, proliferation and apoptosis of human glioma cell lines were measured by Cell Counting kit 8 and flow cytometry. Pathway verification and protein interaction were determined by quantitative real-time polymerase chain reaction, Western blotting and immunofluorescence staining. Transwell technology was used to assess the migration and invasion of cells. Clinical significance of TIMP3, MMP9 and MMP2 in glioma was analyzed through The Cancer Genome Atlas (TCGA) database and the Genotype-Tissue Expression (GTEx) database. RESULTS: Functionally, pracinostat not only inhibited proliferation and induced apoptosis but also inhibited migration and invasion in human glioma cell lines. Mechanistically, pracinostat increased the expression of TIMP3 and decreased the expression of MMP2, MMP9 and VEGF in human glioma cells in vitro and in vivo. In addition, pracinostat inhibited both the PI3K/Akt signaling pathway and the STAT3 pathway. CONCLUSIONS: Our results strongly support the potential clinical use of pracinostat as a novel therapy for human glioma in the near future.
Authors: Andra V Krauze; Sten D Myrehaug; Michael G Chang; Diane J Holdford; Sharon Smith; Joanna Shih; Philip J Tofilon; Howard A Fine; Kevin Camphausen Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-30 Impact factor: 7.038
Authors: Emilie Le Rhun; Matthias Preusser; Patrick Roth; David A Reardon; Martin van den Bent; Patrick Wen; Guido Reifenberger; Michael Weller Journal: Cancer Treat Rev Date: 2019-09-11 Impact factor: 12.111
Authors: Dong Yin; John M Ong; Jinwei Hu; Julian C Desmond; Norihiko Kawamata; Bindu M Konda; Keith L Black; H Phillip Koeffler Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Evanthia Galanis; Kurt A Jaeckle; Matthew J Maurer; Joel M Reid; Matthew M Ames; James S Hardwick; John F Reilly; Andrey Loboda; Michael Nebozhyn; Valeria R Fantin; Victoria M Richon; Bernd Scheithauer; Caterina Giannini; Patrick J Flynn; Dennis F Moore; James Zwiebel; Jan C Buckner Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544
Authors: V Novotny-Diermayr; S Hart; K C Goh; A Cheong; L-C Ong; H Hentze; M K Pasha; R Jayaraman; K Ethirajulu; J M Wood Journal: Blood Cancer J Date: 2012-05-04 Impact factor: 11.037